Yung Fa Chen, ScinoPharm’s President and CEO, documents his strategy to drive the Taiwan-based global success story to new heights, having established itself as an indisputable leader in the API field, providing its international partners with complex, difficult-to-make products. Yung Fa Chen notably explains how he wants to further leverage the company’s unrivalled expertise in the R&D and manufacturing of high-barrier APIs to vertically integrate its offering and make a success of ScinoPharm’s entry in the injectable product field.
Having initially joined the company in 1998, you were appointed President and CEO of ScinoPharm in August 2014. What is the growth strategy you have been implementing since the beginning of your tenure?
"Over the past two years, ScinoPharm has been vertically expanding its offering to now encompass the manufacturing of finished injectable products, while we are ready to increase our contract manufacturing activities and have been tremendously improving the competitiveness of our organization."
